Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Ninerafaxstat by Imbria Pharmaceuticals for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
Ninerafaxstat is under clinical development by Imbria Pharmaceuticals and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart...
Data Insights
Ninerafaxstat by Imbria Pharmaceuticals for Hypertrophic Cardiomyopathy: Likelihood of Approval
Ninerafaxstat is under clinical development by Imbria Pharmaceuticals and currently in Phase II for Hypertrophic Cardiomyopathy. According to GlobalData, Phase...